A Phase 3 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia (AML) and Cancer, sponsored by AbbVie. Completed at 16 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-03-20.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 84th largest by enrollment of the 211 interventional ones that give a count, is one of 9 that started in 2019, is one of 26 in phase 3, and was the 98th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 133 · Phase 3 31 · Phase 4 3
First in 2000; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 211 interventional studies. Of the 100 that completed or were terminated, 43 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 214 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
43 studies in Leukemia, Myeloid, Acute by AbbVie: 4 open now, 10 under way, 3 of them phase 3. Of 31 finished, 7 (23%) have results posted.
Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2019, is one of 7 in phase 3, and was the 21st registered.
AbbVie’s Leukemia, Myeloid, Acute studies by the year they started, since 2010.
25 of the studies testing azacitidine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT06783790Institute of Hematology & Blood Diseases Hospital, ChinaAvapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | 2026-12 |
| NCT06066905Guangdong Provincial People's HospitalA Study of Chidamide With AZA in MRD Positive AML After Transplant | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, from their registry updates:
Among AbbVie’s 43 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
A study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with AML who are ineligible for intensive chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has a history of the following conditions:
Has a history of other within 2 years prior to study entry, with the exception of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Azacitidine (75 mg/m\^2) was administered subcutaneously or intravenously per investigator's choice and institutional practice for 7 days beginning on Day 1 of each 28-day cycle.
Drug: Venetoclax · Drug: Azacitidine
Participants received venetoclax orally daily for 28-day cycles, for a maximum of 6 cycles, beginning on Cycle 1 Day 1. The venetoclax dosing ramp-up schedule was 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, and 400 mg on Cycle 1 Days 3 -28 and 400 mg daily for each 28-day cycle thereafter. Decitabine (20 mg/m\^2) was administered intravenously per investigator's choice and institutional practice for 5 days beginning on Day 1 of each cycle.
Drug: Venetoclax · Drug: Decitabine
Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
Also known as: ABT-199, VENCLEXTA, VENCLYXTO
The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
Also known as: Vidaza
The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
Also known as: Dacogen
Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi)
The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CR: Absolute neutrophil count (ANC) \> 10\^3/μL (1,000/μL), platelets \> 10\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts CRi: Bone marrow with \< 5% blasts, and absolute neutrophils of ≤ 10\^3/μL or platelets ≤ 10\^5/μL
Time frame: Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.
Percentage of Participants With Complete Remission (CR)
The complete remission rate is defined as the percentage of participants with complete remission (CR) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CR: Absolute neutrophil count (ANC) \> 10\^3/μL (1,000/μL), platelets \> 10\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts
Time frame: Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.
Percentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi)
The complete remission with incomplete blood count recovery rate is defined as the percentage of participants with complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CRi: Bone marrow with \< 5% blasts, and absolute neutrophils of ≤ 10\^3/μL or platelets ≤ 10\^5/μL.
Time frame: Assessed at Cycle 1 end, at Cycle 2 end if CR/CRi wasn't achieved at Cycle 1 end, or Cycle 4 end if CR/CRi wasn't achieved at Cycle 2 end. Median treatment duration of venetoclax was 16.1 wks (range 3.9-38.1) and 21.1 wks (range 2.7-40.4), respectively.
Percentage of Participants With Post-baseline Transfusion Independence
The transfusion independence rate is defined as the percentage of participants with post-baseline transfusion independence, which is defined as a period of at least 56 days with no transfusion after the first dose of study drug and within 30 days of the last dose of study drug, death, or initiation of post-treatment therapy, whichever is earliest.
Time frame: From the first dose of study drug to the last dose of study drug +30 days, or death, or initiation of post-treatment therapy, whichever occurred earliest. Median time on follow-up was 183.5 days and 195.0 days, respectively.
| Milestone | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg |
|---|---|---|
| Started | 30 | 30 |
| Completed | 7 | 11 |
| Not completed | 23 | 19 |
| Withdrew: Adverse event | 1 | 8 |
| Withdrew: Progressive disease | 7 | 3 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Death | 3 | 1 |
| Withdrew: Withdrew consent | 1 | 3 |
| Withdrew: Physician decision | 9 | 2 |
| Withdrew: Other, not specified | 2 | 1 |
The composite complete remission rate is defined as the percentage of participants with complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CR: Absolute neutrophil count (ANC) \> 10\^3/μL (1,000/μL), platelets \> 10\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts CRi: Bone marrow with \< 5% blasts, and absolute neutrophils of ≤ 10\^3/μL or platelets ≤ 10\^5/μL
| percentage of participants | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg |
|---|---|---|
| Percentage of Participants With Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR + CRi) | 70.0 (50.6 to 85.3) | 63.3 (43.9 to 80.1) |
The complete remission rate is defined as the percentage of participants with complete remission (CR) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CR: Absolute neutrophil count (ANC) \> 10\^3/μL (1,000/μL), platelets \> 10\^5/μL (100,000/μL), red blood cell (RBC) transfusion independence, and bone marrow with \< 5% blasts
| percentage of participants | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg |
|---|---|---|
| Percentage of Participants With Complete Remission (CR) | 13.3 (3.8 to 30.7) | 26.7 (12.3 to 45.9) |
The complete remission with incomplete blood count recovery rate is defined as the percentage of participants with complete remission with incomplete blood count recovery (CRi) at any time during the study as assessed by the investigator. Response was based on bone marrow results and hematology values according to the modified International Working Group (IWG) criteria for AML: CRi: Bone marrow with \< 5% blasts, and absolute neutrophils of ≤ 10\^3/μL or platelets ≤ 10\^5/μL.
| percentage of participants | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg |
|---|---|---|
| Percentage of Participants With Complete Remission With Incomplete Blood Count Recovery (CRi) | 56.7 (37.4 to 74.5) | 36.7 (19.9 to 56.1) |
The transfusion independence rate is defined as the percentage of participants with post-baseline transfusion independence, which is defined as a period of at least 56 days with no transfusion after the first dose of study drug and within 30 days of the last dose of study drug, death, or initiation of post-treatment therapy, whichever is earliest.
| percentage of participants | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg |
|---|---|---|
| Red blood cells (RBC) | 50.0 (31.3 to 68.7) | 60.0 (40.6 to 77.3) |
| Platelets | 73.3 (54.1 to 87.7) | 73.3 (54.1 to 87.7) |
| RBC and platelets | 50.0 (31.3 to 68.7) | 60.0 (40.6 to 77.3) |
Collected over All-cause mortality is reported from enrollment to end of study; median time on follow up was 183.5, 195.0 and 195.0 days, respectively. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean time on venetoclax was 18.2, 18.6, and 18.4 weeks, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Venetoclax 400 mg + Azacitidine 75 mg | 5/30 (16.7%) | 19/30 (63.3%) | 29/30 (96.7%) |
| Venetoclax 400 mg + Decitabine 20 mg | 8/30 (26.7%) | 22/30 (73.3%) | 30/30 (100%) |
| Venetoclax 400 mg + Azacitidine 75 mg or Decitabine 20 mg | 13/60 (21.7%) | 41/60 (68.3%) | 59/60 (98.3%) |
| Event | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg | Venetoclax 400 mg + Azacitidine 75 mg or Decitabine 20 mg |
|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 8/30 | 10/30 | 18/60 |
| SEPSISInfections and infestations | 2/30 | 8/30 | 10/60 |
| PYREXIAGeneral disorders | 0/30 | 3/30 | 3/60 |
| HYPOTENSIONVascular disorders | 3/30 | 0/30 | 3/60 |
| PANCYTOPENIABlood and lymphatic system disorders | 2/30 | 0/30 | 2/60 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 2/30 | 1/30 | 3/60 |
| DEATHGeneral disorders | 2/30 | 2/30 | 4/60 |
| DISEASE PROGRESSIONGeneral disorders | 2/30 | 1/30 | 3/60 |
| PNEUMONIAInfections and infestations | 2/30 | 1/30 | 3/60 |
| TUMOUR LYSIS SYNDROMEMetabolism and nutrition disorders | 2/30 | 0/30 | 2/60 |
| Event | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg | Venetoclax 400 mg + Azacitidine 75 mg or Decitabine 20 mg |
|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 23/30 | 24/30 | 47/60 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 19/30 | 15/30 | 34/60 |
| NAUSEAGastrointestinal disorders | 17/30 | 15/30 | 32/60 |
| PLATELET COUNT DECREASEDInvestigations | 14/30 | 16/30 | 30/60 |
| WHITE BLOOD CELL COUNT DECREASEDInvestigations | 15/30 | 16/30 | 31/60 |
| VOMITINGGastrointestinal disorders | 13/30 | 3/30 | 16/60 |
| FATIGUEGeneral disorders | 13/30 | 12/30 | 25/60 |
| DIARRHOEAGastrointestinal disorders | 12/30 | 11/30 | 23/60 |
| CONSTIPATIONGastrointestinal disorders | 11/30 | 8/30 | 19/60 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 3/30 | 10/30 | 13/60 |
All participants who received at least one dose of venetoclax and azacitidine or decitabine
| Age, Continuous(years) | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg | Total |
|---|---|---|---|
| Mean | 77.0 ± 6.31 | 76.2 ± 6.35 | 76.6 ± 6.29 |
| Sex: Female, Male(Participants) | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg | Total |
|---|---|---|---|
| Female | 15 | 16 | 31 |
| Male | 15 | 14 | 29 |
| Race/Ethnicity, Customized(Participants) | Venetoclax 400 mg + Azacitidine 75 mg | Venetoclax 400 mg + Decitabine 20 mg | Total |
|---|---|---|---|
| White | 26 | 29 | 55 |
| Black or African American | 4 | 1 | 5 |
| Asian | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Aug 2019 to primary completion in Mar 2022, 30 months.
Results were first posted in Mar 2023, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 30 months is below that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azacitidine · Decitabine